This week, all eyes have been on the King Review interim report, as stakeholders released their formal responses
Most stakeholders, it’s fair to say, weren’t thrilled with the Interim Report and made it very clear in their submissions, which were made public over the week.
The group representing CSO wholesalers, National Pharmaceutical Services Association, warned of the dangers of switching supply to a Manufacturer Distribution Model, and argued that a threat to wholesaler trading terms was a threat to community pharmacy.
The SHPA is concerned that the report doesn’t give hospital pharmacists the attention they’re due as an “untapped resource”.
The Guild was scathing in its criticism, saying the interim report contains serious errors and a “pre-conceived agenda” to shake up the sector.
The Medicines Partnership members also got together to pan the review… read a roundup of their comments here.
In other news, over the last weekend the Pharmaceutical Society of Australia released a report card on pharmacy services… and found we’re slipping behind other Western nations.
And the GP-pharmacist turf war is still bubbling away, with the focus this week turning to codeine as well as the King Review, where the RACGP‘s submission calls for a downscaling of pharmacy services, GP dispensing and the breaking of the “retail-medicine link,” where CMs are concerned.
Reckitt Benckiser has settled the class action over its Nurofen Specific range. The Fentanyl shortage continues, though shortage for one brand has been resolved. And the rollout of the new TerryWhite Chemmart brand is going gangbusters.